• 1
    Walker JL, Knight EL. Renal cell carcinoma in pregnancy. Cancer 1986;17:23437.
  • 2
    Gleicher N, Deppe G, Cohen CJ. Common aspects immunologic tolerance in pregnancy and malignancy. Obstet Gynecol 1979;54:33542.
  • 3
    Barber HR. Malignant disease in pregnancy. J Perinat Med 2001;29:97111.
  • 4
    Lambe M, Lindblad P, Wuu J, Remier R, Hsieh C. Pregnancy and risk of renal cell cancer: a population-based study in Sweden. Br J Cancer 2002;86:14259.
  • 5
    Selli C, Bartolozzi C, Amorosi A, Carini M. Incidental finding of renal cell carcinoma with histological regressive aspects in a pregnant woman. Eur Urol 1988;15:2879.
  • 6
    Usta IM, Chammas M, Khalil AM. Renal cell carcinoma with hypercalcemia complicating a pregnancy: case report and review of the literature. Eur J Gynaecol Oncol 1998;19:5847.
  • 7
    Lesourd B, Siquier J, Haillot O, Lanson Y. Nephrectomy for cancer in pregnant women. Apropos of a case. J Urol (Paris) 1997;103:5961.
  • 8
    Dakir M, Aboutaieb R, Dahami Z, Ghazli M, Benjelloun S. Kidney cancer and pregnancy. Prog Urol 2001;11:126973.
  • 9
    Gladman MA, MacDonald D, Webster JJ, Cook T, Williams G. Renal cell carcinoma in pregnancy. J R Soc Med 2002;95:199201.
  • 10
    Smith DP, Goldman SM, Beggs DS, Lanigan PJ. Renal cell carcinoma in pregnancy: report of three cases and review of the literature. Obstet Gynecol 1994;83:81820.
  • 11
    Ceglowska A, Michalski A. Renal cell carcinoma during pregnancy. Ginekol Pol 2004;75:1459.
  • 12
    Mancuso A, Macrì A, Palmara V, Scuderi G, Grosso M, Famulari C. Chromophobe renal cell carcinoma in pregnancy: case report and review of the literature. Acta Obstet Gynecol Scand 2001;80:96771.
  • 13
    Cappello F, Palma A, Martorana A et al. Biological aggressiveness evaluation in prostate carcinomas: immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3 + 3) adenocarcinomas. Eur J Histochem 2003;47:12932.
  • 14
    Cappello F, Bellafiore M, Palma A, Bucchieri F. Defective apoptosis and tumorigenesis: role of p53 mutation and Fas/FasL system dysregulation. Eur J Histochem 2002;46:199208.
  • 15
    Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:19518.
  • 16
    Black AP, Bailey A, Jones L, Turner RJ, Hollowood K, Ogg GS. p53-specific CD8+ T-cell responses in individuals with cutaneous squamous cell carcinoma. Br J Dermatol 2005;153:98791.
  • 17
    Espenschied J, Lamont J, Longmate J et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003;170:34017.
  • 18
    Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002;86:88692.
  • 19
    Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy. J Gastrointest Surg 2003;7:7786.
  • 20
    Rodel F, Hoffmann J, Grabenbauer GG et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:42635.
  • 21
    Kyokane K, Ito M, Sato Y, Ina K, Ando T, Kusugami K. Expression of Bcl-2 and p53 correlates with the morphology of gastric neoplasia. J Pathol 1998;184:3829.
  • 22
    Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004;25:25863.
  • 23
    Pelosi G, Bresaola E, Rodella S et al. Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations. Diagn Cytopathol 1994;11:13140.
  • 24
    Serio G. PCNA/cyclin expression in transitional cell carcinomas of the human bladder: its correlation with Ki-67 and epidermal growth factor receptor immunostainings. Pathologica 1994;86:1616.
  • 25
    Krecicki T, Jelen M, Zalesska-Krecicka M, Rak J, Szkudlarek T, Jelen-Krzeszewska J. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 1999;35:1806.
  • 26
    Gurer IE, Simsek T, Erdogan G et al. The utilization of immunohistochemical prognostic factor in endometrial adenocarcinoma: is it cost effective? Eur J Gynaecol Oncol 2000;21:1979.
  • 27
    Liu SC, Klein-Szanto AJ. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 2000;36:14551.